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Between 1962 and 1991, 72 patients (mean age 63.4 years) underwent sleeve 
lobectomy for primary lung cancer. Thirty-seven patients had adequate 
lung function and 35 were deemed unsuitable for pneumonectomy on the 
basis of inadequate pulmonary reserve (n = 31) or cardiac risk factors (n = 
4). Squamous cell carcinomas (68%) and adenocarcinomas (26%) predom- 
inated. Upper lobectomy was performed in 48 patients, lower and middle 
lobectomy in 13, and right upper and middle bilobectomy in 11. Hospital 
mortality was 4% (3/72) and compares with a hospital mortality of 9% in 56 
consecutive pneumonectomies between 1986 and 1990. Major complications 
occurred in 11% (bronchopleural fistula 1, persistent atelectasis 4, pneu- 
monia 4). Adjusted actuarial survival after sleeve lobectomy at 1 and 5 
years was 84% and 42%, compared with 76% and 44% after pneumonec- 
tomy. Five-year survival after lower and middle lobectomy in 13 patients 
(52%) was similar to that after upper lobectomy (46%), suggesting that in 
carefully selected patients the concept of sleeve lobectomy can be applied to 
all pulmonary lobes. NI disease and compromised lung function were 
associated with lower survival (N1 38% vs NO 57%; compromised 20% vs 
adequate 55%). Comparison of preoperative and postoperative lung func- 
tion and quantitative ventilation-perfusion isotope studies substantiated 
the preservation of pulmonary function in this group of patients. Sleeve 
lobectomy is the procedure of choice for anatomically suitable carcinomas 
or when reduced pulmonary reserve precludes extensive resection. 
(J Thorac Cardiovasc Surg 1996;111:948-53) 
~leeve resection of the bronchus has changed the 
K/management of benign tumors and altered the 
approach to selected malignant bronchogenic neo- 
plasms.2, 3 Bronchoplastic procedures for lung can- 
cer were originally designed for patients with com- 
promised pulmonary function unable to tolerate 
pneumonectomy. As it became likely that sleeve 
lobectomy ielded survival results at least equal to 
those of pneumonectomy, and yielded better func- 
tional results, it became an accepted procedure for 
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patients with lung cancer who have anatomically 
suitable tumors, regardless of pulmonary function. 
Limited information is available regarding long- 
term functional results and survival despite the 
growing experience with sleeve lobectomy. Early 
postoperative lung dysfunction after sleeve lobec- 
tomy has been demonstrated in animals and human 
beings 4, 5 but does not appear to affect long-term 
performance. It has been assumed that preserved 
lung functions normally, but little information exists 
to confirm this assumption. 
The reported 5-year survival for sleeve lobectomy 
ranges from 18% to 67%, depending on stage and 
pulmonary functional reserve. 6-9 Patients with nor- 
mal lung function achieve better long-term survival 
than those with compromised function. No random- 
ized trials comparing sleeve lobectomy with pneu- 
monectomy have been performed, and they are not 
likely to be performed. Thus the available informa- 
tion is derived from unmatched, retrospective co- 
horts of patients. 
We have reviewed our experience with sleeve 
lobectomy in a consecutive series of 72 patients to 
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verify or refute results obtained by others. We 
determined perioperative morbidity and mortality, 
long-term survival, and late functional results. Be- 
cause pneumonectomy is the surgical alternative to 
sleeve lobectomy, we chose a recent 5-year interval 
to compare morbidity, mortality, and survival when 
appropriate in a consecutive, unmatched group of 
patients undergoing pneumonectomy for lung can- 
cer. 
Patients and methods 
Seventy-two patients underwent sleeve lobectomy for 
bronchogenic carcinoma at the Massachusetts General 
Hospital from 1962 to 1991. Resections involving the 
carina were excluded. Information was gathered from 
hospital charts, office records , and personal contact with 
patients and their families. Inasmuch as the surgical 
alternative to sleeve lobectomy is pneumonectomy, a 
consecutive, unmatched series of 56 patients undergoing 
pneumonectomy for bronchogenic arcinoma between 
1986 and 1990 at the same institution provided some 
comparison of perioperative morbidity, mortality, and 
long-term survival; the comparison is somewhat prejudi- 
cial to sleeve lobectomy, in view of the recency of the 
pneumonectomy operations. Although no attempt was 
made to match the groups, they were fairly comparable in
terms of age, sex, histology, stage, and nodal status (Table 
I). 
Statistical methods. Cumulative survival was calcu- 
lated according to the actuarial method of Cutler and 
Ederer modified by Anderson and associates. 1°
Preoperative evaluation. Computed axial tomograms 
of the chest, upper part of the abdomen, and adrenal 
glands, or linear tomograms in those operated on before 
1976, were obtained in all patients. Metastatic workup 
including head computed tomography and bone scan was 
performed when indicated. Preoperative pulmonary func- 
tion studies were done in all patients to determine first- 
second forced expiratory volume (FEV 0 and forced vital 
capacity. Quantitative ventilation and perfusion radionu- 
clide scans were performed in 50 patients (69%). Postop- 
erative FEV 1 was predicted by the formula: postoperative 
FEV 1 = preoperative FEV 1 x percent function of lung 
regions not to be resectedJ 1 A predicted postoperative 
FEV 1 of less than 800 ml/sec was considered a contrain- 
dication for pneumonectomy. On the basis of clinical and 
objective functional assessment, 37 patients had adequate 
pulmonary function to tolerate pneumonectomy and 35 
patients were not in suitable condition for pneumonec- 
tomy. Twenty-five had inadequate lung function at spi- 
rometry to tolerate pneumonectomy, seven had clinical 
signs of inadequate lung function, two had cardiovascular 
contraindications, one was elderly, and one had multiple 
sclerosis. 
Surgical technique. The procedure for sleeve lobec- 
tomy is identical to that for standard lobectomy until the 
bronchus is isolated. A single sharp incision divides the 
bronchus and thus avoids ragged edges. Care is taken not 
to devascularize the bronchus beyond the proposed line of 
transection. We refrain from any handling of the bron- 
Table I. Patient characteristics* 
Sleeve 
lobectomy Pneumonectomy 
(n = 72): (n = 56): 
1962-1991 1986-1990 
No. % No. % 
Men 56 78 42 75 
Women 16 22 14 25 
Histology 
Squamous 49 68 33 59 
Adenocarcinoma 19 26 17 30 
Large cell 3 4.2 2 3.5 
Adenosquamous 1 1.4 2 3.5 
Bronchoalveolar 2 3.5 
Stage 
I 29 40 9 16 
II 31 43 25 45 
III 12 17 21 37 
IV 1 2 
Nodal stage 
NO 31 43 15 26 
N1 34 47 32 57 
N2 7 10 9 17 
*Mean age for the sleeve lobectomy group was 63.4 years (range 35 to 86 
years) and for the pneumonectomy group, 60.8 years (range 37 to 77 
years). 
chial mucosa. Frozen section analysis is usually performed 
by sending a thin ring of tissue from the two ends of the 
airway to be anastomosed. No attempt is made to tailor 
either end of the bronchus. Traction sutures of 2-0 Vicryl 
polyglactin 910 (Ethicon, Inc., Somerville, N.J.) are placed 
proximal and distal in the mid-lateral position of the 
bronchial wall. Individual sutures of 4-0 Vicryl polyglactin 
910 are evenly placed. Proper spacing of the sutures will 
accommodate any size discrepancy between the two ends 
of the airway. After approximation of the traction sutures, 
the sutures are tied circumferentially with the knots on the 
outside. The anastomosis i checked for air leaks by 
inflating the lung after filling the thorax with saline 
solution. The suture line is inspected with a flexible 
bronchoscope atthis point. Pedicled pleura or pericardial 
fat is used to wrap the bronchus to separate the suture line 
from vascular structures. 
Results 
Age and sex. The sleeve lobectomy group con- 
sisted of 56 men and 16 women with a mean age of 
63.4 years (range 35 to 86 years). The pneumonec- 
tomy group comprised 42 men and 14 women. Their 
ages ranged from 37 to 77 years with a mean of 60.8 
years. 
Staging and histology. Histologic characteristics 
for both groups are seen in Table I. Sixty-one 
patients had mediastinoscopy and three patients had 
a Chamberlain procedure before sleeve lobectomy. 
All but three of the patients had disease-free medi- 
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Fig. 1. Actuarial survival after sleeve lobectomy by stage. 
astinal nodes. The three patients with diseased N2 
nodes were entered into a neoadjuvant treatment 
protocol. In the pneumonectomy group, 42 patients 
underwent mediastinoscopy and six a Chamberlain 
procedure. Postoperative pathologic staging for 
both groups is given in Table I. 
Indication for sleeve lobectomy. The presence of 
an endobronchial tumor identified uring bronchos- 
copy precluded standard lobectomy in 54 patients. 
In the other 18 patients, the decision for sleeve 
lobectomy was made during thoracotomy. Meta- 
static lymph nodes adherent o the origin of the 
lobar bronchus were found in eight patients. Direct 
extension from central tumors onto the wall of the 
bronchus not detected by bronchoscopic study was 
seen in six patients. Unsuspected involvement of the 
bronchial margins was diagnosed by frozen section 
in four patients and necessitated sleeve lobectomy. 
Type of resection. Right upper sleeve lobectomy 
was performed in 38 patients (53%), sleeve lobec- 
tomy of right upper and middle lobes in 11 (15%), 
left upper lobe in 10 (14%), left lower lobe in six 
(8%), right middle lobe in three (4%), and right 
middle and lower lobes in three (4%), and right 
lower lobe in one. When the middle and right upper 
lobes were resected together, the middle lobe bron- 
chus was taken separately and not included in the 
bronchial sleeve s in eight patients, and it was taken 
with the sleeve in three. Concomitant chest wall 
resection was done in three patients. Sleeve resec- 
tion of the pulmonary artery was performed in two 
patients with compromised lung function and lateral 
resection of the artery in one other patient. 
Mortality and morbidity. Three deaths occurred 
after sleeve lobectomy, resulting in a hospital mor- 
tality of 4%. Causes of death were ventricular 
fibrillation on day 2, myocardial infarction on day 8 
in a patient with concomitant sleeve resection of the 
pulmonary artery, and Pseudomonas pneumonia on 
Table II. Morbidity 
Sleeve lobectomy Pneumonectomy 
Major complications (n = 72) (n = 56) 
Bronchpleural fistula 1 1 
Pneumonia 3 2 
Cerebrovascular ccident 1 
Pulmonary embolus 1 
Deep vein thrombosis 1 
Herniation of heart 1 
Persistent atelectasis 4 1 
Total 8 [11% 1 8 [14% 1 
day 33. No hospital deaths have occurred in 42 
consecutive patients ince 1986, and no deaths have 
occurred during the entire series in patients with 
adequate pulmonary function. 
Sleeve lobectomy. Major complications occurred 
in eight patients (11%). One patient had a broncho- 
pleural fistula, which necessitated operative repair 2 
weeks after lobectomy and was followed by an 
empyema and prolonged mechanical ventilation. 
Three patients had pneumonia nd four had persis- 
tent atelectasis necessitating repeated broncho- 
scopic treatment for bronchial toilet. Supraventric- 
ular tachycardias occurred in nine patients. 
Late bronchial stenosis. Bronchial stenosis at the 
site of the anastomosis developed in two patients. 
One underwent pneumonectomy 1 year later for 
retained secretions and recurrent pneumonia. The 
other patient required several dilatations and has a 
stable narrowing of the anastomosis with normally 
functioning lung on the side of the operation 6years 
later. 
Pneumonectomy. The hospital mortality in 56 pa- 
tients undergoing pneumonectomy for broncho- 
genic carcinoma was 9%. The cause of death in five 
patients was adult respiratory distress syndrome 
(n = 2), bronchopleural fistula (n = 1), pneumonia 
(n = 1), and myocardial infarction (n = 1). Major 
complications occurred in 16% (9/56), consisting of 
pulmonary embolus (n = 2), pneumonia (n = 2), 
cardiac herniation after pericardial resection (n = 
1), bronchpleural fistula (n = 1), stroke (n = 1), 
deep vein thrombosis (n = 1), and atelectasis (n = 
1). Seven patients had supraventricular tachycardia. 
Radiotherapy. Radiotherapy was administered on 
the basis of the surgeon's judgment, most often for 
hilar lymph node involvement. Twenty-seven pa- 
tients received postoperative radiation. The indica- 
tion in 19 was N1 disease and in two N2 disease. The 
remaining six patients received postoperative radio- 
therapy for diseased bronchial margins on perma- 
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Fig. 2. Comparison of survival after sleeve lobectomy 
and pneumonectomy in patients with stage II disease. 
Error bars show 95% confidence limits. 
nent sections (n = 2), carcinoma-in-situ atthe bron- 
chial margin (n = 2), and diseased venous resection 
margins (n = 2). Three patients early in the series had 
preoperative radiation, and three with N2 disease 
underwent preoperative and postoperative radiation 
therapy as part of a multimodality protocol. 
Follow-up and survival. Follow-up was complete 
except for one patient in each group. Mean fol- 
low-up was 47 _+ 46 months (mean + standard 
deviation, range 3 to 268 months) after sleeve 
lobectomy and 37 _+ 25 months (range 2 to 80 
months) after pneumonectomy. Included in survival 
calculations were two patients who underwent pul- 
monary resection for a second primary lung cancer 9 
and 12 months after sleeve lobectomy. 
Actuarial survival by stages in the sleeve lobec- 
tomy group is given in Fig. 1. Actuarial survival after 
sleeve lobectomy was 80% _+ 4.8% (mean + stan- 
dard error) at 1 year and 42% -+ 6.5% at 5 years. 
These figures compare with actuarial survivals after 
pneumonectomy of 76% + 5.9% at 1 year and 
44% _+ 7.3% at 5 years. Fig. 2 shows that the survival 
in patients with stage II disease after sleeve lobec- 
tomy and pneumonectomy was comparable. Survival 
data were not calculated for pneumonectomy pa- 
tients with stage I and II! disease because of the 
small numbers. Fig. 3 compares the survival of 
patients whose functional status was compromised 
and that of patients whose status was adequate. 
Comparison of survival between 47 patients 
undergoing sleeve resection of the upper lobe 
(adequate function, 24 patients; compromised 
function, 23 patients) and 13 patients with middle 
and lower sleeve lobectomies (adequate,. 7 pa- 
tients; compromised, 5 patients) is demonstrated 
in Fig. 4. Survival at 5 years was 46% _+ 8.5% after 
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Fig. 3. Actuarial survival in patients with compromised 
and adequate lung function. Error bars show 95% confi- 
dence limits. 
100~ 
90- 
80- 
70- 
60- 
> 
r r  50- 
40- 
30- 
20- 
10-  -'O- MIDDDLE / LOWER LOBECTOMY (n=13) 
0 
"'"1.. 
"m"l'~ ................. {~51 
m UPPERLOBECTOMY(n=47) 
i i i L i 
1 2 3 4 5 
YEARS 
Fig. 4. Actuarial survival in patients after upper versus 
middle and lower lobectomy. Error bars show 95% confi- 
dence limits. 
upper lobectomy and 52% -2-_ 14% after middle and 
lower lobectomy. Thirty-one patients with NO disease 
had !- and 5-year adjusted survivals of 93% -+ 4.6% 
and 57% _+ !0%. Survival in 33 patients with N1 
disease was 79% _+ 7.1% and 38% _+ 9.3% and in 
seven patients with N2 disease, 57% _+ 19% and 
43% _+ 19%, respectively. Thirty-six patients not re- 
quiring radiation therapy had 91% _+ 4.9% survival at 
! year and 58% +_ 9.4% at 5 years, compared with 69% 
+_ 8.0% and 30% _+ 8.8% in 33 patients undergoing 
radiotherapy. The patients receiving radiotherapy 
could be expected to have a worse prognosis because 
the indication for this therapy was diseased nodes or 
margins. 
Local recurrence. Locoregional recurrence devel- 
oped in 10 patients after sleeve lobectomy (14%; 
10/69). Tumor recurred in the mediastinum in seven 
patients and in the ipsilateral ung in two; one 
patient had a confirmed suture-line recurrence. 
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16 patients. Predicted FEV 1 was derived from preopera- 
tive pulmonary function tests and quantitative ntilation- 
perfusion scan. 1! Correlation coefficient is 0.87. 
Prediction of postoperative FEVp In 16 patients 
with sleeve lobectomy, preoperative and postop- 
erative pulmonary function studies and preopera- 
tive quantitative ventilation-perfusion scans were 
available for comparison. Postoperative pulmo- 
nary function studies were obtained 4 months to 
11 years (mean 3.5 years) after resection, and 
eight patients had received radiotherapy. Com- 
parison O f predicted and observed FEV1, shown in 
Fig. 5, demonstrates that perfusion-derived data 
served as a good estimation of postoperativ e 
function, with a correlation coefficient of 0.87. 
Predicted values overestimated observed values 
on average by 15%. 
Ventilation-peifusion scans. Eight patients had 
preoperative and postoperative quantitative ventila- 
tion-perfusion lung scans 1 to 11 years (mean 4.5 
years) after sleeve lobectomy (right upper lobe, 5; 
left upper lobe, 1; right upper and middle lobes, 1; 
left lower lobe, 1). Three had undergone postoper- 
ative radiotherapy. On the side of the operation, 
mean postoperative p rfusion ratio was 35% (range 
21% to 48%). The lowest perfusion values were 
observed in a patient with postoperative bronchial 
stenosis (21%) and after radiation therapy (22%). 
Mean postoperative ventilation ratio was 44% 
Table III 
Predicted Observed 
Preoperative postoperative postoperative 
FEV 1 (L/rain) 3.28 (2.43-4.04) 2.80 (2.2-3.4) 2.74 (2.06-3.66) 
Perfusion (%) 44.5 (35-48) 31.4 (24-39) 35.0 (21-48) 
Ventilation (%) 46.2 (38-54) 31.7 (22-39) 46.2 (32-56) 
Comparison of preoperative to predicted and observed postoperative 
parameters of pulmonary function in eight patients on the operated side. 
Numbers represent mean values and their range. 
(range 32% to 51%). Table III compares preopera- 
tive to predicted and observed postoperative FEV 1 
and ventilation/perfusion ratios on the side of the 
operation. 
Discussion 
Sleeve lobectomy for anatomically suited lung 
cancers has become the procedure of choice for 
patients with compromised and noncompromised 
lung function. Before the development of segmental 
bronchial resection, cancers of the origin of the 
lobar bronchus necessitated pneumonectomy to re- 
move all of the cancer. No prospective studies 
comparing sleeve lobectomy and pneumonectomy 
have been conducted. Comparable mortality and 
survival for both procedures have been demon- 
strated in retrospective studies. 6'7 In our series, the 
entire group of patients having sleeve lobectomies 
had an operative mortality of 4%, compared with 
9% for the pneumonectomy group. No deaths re- 
lated to the operation occurred among patients with 
adequate function undergoing sleeve resection. Ma- 
jor complications were more common after pneu- 
monectomy (16%) than after sleeve lobectomy 
(11%). Although the comparison of these two 
groups was retrospective and nonrandomized, these 
data suggest he superiority of sleeve lobectomy 
over pneumonectomy in selected patients. 
The overall survival after sleeve lobectomy is 
virtually identical to that after pneumonectomy in 
our series. Analysis of subsets within the sleeve 
lobectomy group indicates improved survival for 
patients with noncompromised lung function com- 
pared with compromised function (55% vs 20% 
5-year survival) and for patients with NO compared 
with N1 disease (57% vs 38% at 5 years). 12 The 
difference in survival between patients who did or 
did not receive radiation therapy reflects nodal 
status, because the indication for radiation therapy 
was predominantly hilar or mediastinal nodal in- 
volvement. Comparison of survival between sleeve 
lobectomy and pneumonectomy according to nodal 
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status and stage demonstrated little difference be- 
tween the two procedures ( ee Fig. 2). 
Limited information is available on the outcome 
after sleeve resection of the middle and lower lobes. 
Weisel and associates 6 reported eight lower lobecto- 
mies in 70 patients and Firmin and colleagues s re- 
ported four lower lobe resections among 90 patients. 
Middle and lower sleeve lobectomies are done less 
often because suitable intrabronchial lesions are rare. 
Furthermore, on the basis of studies on the lymphatic 
spread of lung cancer, some authors believe that a 
bronchoplastic procedure does not adequately encom- 
pass central tumors of the lower and middle lobes and 
thus results in inferior tumor clearance. In our series 
the actuarial survival was 52% for 13 patients with this 
type of resection compared with 46% after upper 
sleeve lobectomy. These data suggest that the concept 
of parenchyma-preserving resection can be applied to 
all pulmonary lobes. 
Chances for survival appear emote when sleeve 
resection is performed for carcinomas invading the 
bronchial wall from the peribronchial tissues and 
not from the luminal side. This indication was 
present in six patients without intrabronchial tumor, 
of whom three had stage I disease, one stage II, and 
two stage III disease. All except one patient would 
not have tolerated a more radical procedure on the 
basis of preoperative lung function. Five of them 
died 6 to 22 months after operation of recurrent 
tumor and one was lost early to follow-up. Careful 
consideration of pneumonectomy ust be given to 
this group of patients if lung function permits. 
With survival equal to or greater than after pneu- 
monectomy, the principal benefit of sleeve lobectomy 
has been the ability to preserve lung parenchyma. 9' 13 
Preoperative assessment predicted postoperative lung 
function reliably in our patients. Quantitative ntila- 
tion and perfusion scans demonstrated that the con- 
tribution to postoperative lung function was propor- 
tionally distributed between the preserved lung that 
had been operated on and the contralateral side. 
Mean postoperative perfusion to the side of the oper- 
ation was 35% in these patients after upper or lower 
lobectomy, indicating that the expected proportion of 
pulmonary blood flow is directed to the preserved 
lung. 
In patients with adequate lung function, sleeve 
lobectomy should never compromise the cancer 
operation. Locoregional recurrence developed in 10 
of 69 patients (14%). In seven patients, tumors 
recurred in the mediastinum, where tumor clear- 
ance would unlikely be improved by a pneumonec- 
tomy. Only three patients had a local recurrence in
the ipsilateral lung (n = 2) or at the suture line (n = 
1). Pneumonectomy ay offer little additional ad- 
vantage for close bronchial margins unless carinal 
resection is considered. Clinical judgment must be 
exercised to decide between sleeve lobectomy and 
pneumonectomy in some patients with central peri- 
hilar neoplasms. 
Sleeve lobectomy is indeed the procedure of 
choice in patients with lung cancer who have ana- 
tomically suited tumors for this procedure. Survival 
is acceptable and appears comparable with the 
surgical alternative of pneumonectomy. Improved 
quality of life can be expected because of the 
preservation of functioning lung. 
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